116 related articles for article (PubMed ID: 12543792)
21. Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model.
Yanagie H; Tanabe T; Sumimoto H; Sugiyama H; Matsuda S; Nonaka Y; Ogiwara N; Sasaki K; Tani K; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 May; 63(4):275-86. PubMed ID: 18657378
[TBL] [Abstract][Full Text] [Related]
22. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
Thorne SH; Tam BY; Kirn DH; Contag CH; Kuo CJ
Mol Ther; 2006 May; 13(5):938-46. PubMed ID: 16469543
[TBL] [Abstract][Full Text] [Related]
23. Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated -7 (mda-7)/interleukin-24 (IL-24) gene.
Saito Y; Miyahara R; Gopalan B; Litvak A; Inoue S; Shanker M; Branch CD; Mhashilkar AM; Roth JA; Chada S; Ramesh R
Cancer Gene Ther; 2005 Mar; 12(3):238-47. PubMed ID: 15578066
[TBL] [Abstract][Full Text] [Related]
24. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
[TBL] [Abstract][Full Text] [Related]
25. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
26. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
27. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer.
Liu X; Elojeimy S; El-Zawahry AM; Holman DH; Bielawska A; Bielawski J; Rubinchik S; Guo GW; Dong JY; Keane T; Hannun YA; Tavassoli M; Norris JS
Mol Ther; 2006 Nov; 14(5):637-46. PubMed ID: 16887394
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy of prostate xenograft tumors with a p75NTR lipoplex.
Allen J; Khwaja F; Djakiew D
Anticancer Res; 2004; 24(5A):2997-3003. PubMed ID: 15517907
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene.
Ishikawa H; Nakao K; Matsumoto K; Ichikawa T; Hamasaki K; Nakata K; Eguchi K
Hepatology; 2003 Mar; 37(3):696-704. PubMed ID: 12601367
[TBL] [Abstract][Full Text] [Related]
30. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase.
Abarzua F; Sakaguchi M; Takaishi M; Nasu Y; Kurose K; Ebara S; Miyazaki M; Namba M; Kumon H; Huh NH
Cancer Res; 2005 Nov; 65(21):9617-22. PubMed ID: 16266978
[TBL] [Abstract][Full Text] [Related]
31. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model.
Zhu DE; Höti N; Song Z; Jin L; Wu Z; Wu Q; Wu M
Cancer Gene Ther; 2006 Aug; 13(8):762-70. PubMed ID: 16543917
[TBL] [Abstract][Full Text] [Related]
32. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
Cozzi PJ; Burke PB; Bhargav A; Heston WD; Huryk B; Scardino PT; Fong Y
Prostate; 2002 Oct; 53(2):95-100. PubMed ID: 12242723
[TBL] [Abstract][Full Text] [Related]
34. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
35. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody.
Popkov M; Jendreyko N; McGavern DB; Rader C; Barbas CF
Cancer Res; 2005 Feb; 65(3):972-81. PubMed ID: 15705898
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
[TBL] [Abstract][Full Text] [Related]
38. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
39. An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo.
Iuliano R; Trapasso F; Le Pera I; Schepis F; Samà I; Clodomiro A; Dumon KR; Santoro M; Chiariotti L; Viglietto G; Fusco A
Cancer Res; 2003 Feb; 63(4):882-6. PubMed ID: 12591742
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
